We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
FAGR.BR

Price
18.12
Stock movement down
-0.12 (-0.66%)
Company name
Fagron NV
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Markedsverdi
1.32B
Ent verdi
1.79B
Pris/omsetning
1.11
Pris/bok
2.77
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
39.87%
Etterfølgende P/E
11.89
Fremtidig P/E
14.02
PEG
-
EPS-vekst
10.36%
1 års avkastning
8.31%
3 års avkastning
4.74%
5 års avkastning
-2.48%
10 års avkastning
-5.49%
Sist oppdatert: 2024-12-21

UTBYTTE

FAGR.BR betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E11.89
Pris til OCF7.72
Pris til FCF13.02
Pris til EBITDA5.07
EV i forhold til EBITDA6.88

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning1.11
Pris til bok2.77
EV i forhold til salg1.50

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall72.84M
EPS (TTM)1.52
FCF per aksje (TTM)1.39

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)1.19B
Bruttofortjeneste (TTM)246.81M
Driftsinntekter (TTM)173.29M
Netto inntekt (TTM)110.97M
EPS (TTM)1.52
EPS (1 år fremover)1.29

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)20.70%
Driftsmargin (TTM)14.53%
Fortjenestemargin (TTM)9.31%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter96.69M
Netto fordringer86.62M
Samlede omløpsmidler348.24M
Goodwill448.22M
Immaterielle eiendeler48.54M
Eiendom, anlegg og utstyr0.00
Sum eiendeler1.05B
Leverandørgjeld117.11M
Kortsiktig/nåværende langsiktig gjeld362.76M
Sum kortsiktig gjeld200.47M
Sum gjeld567.95M
Aksjonærenes egenkapital477.11M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)170.95M
Kapitalutgifter (TTM)69.55M
Fri kontantstrøm (TTM)101.40M
Utbetalt utbytte (TTM)40.43M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning23.26%
Avkastning på eiendeler10.62%
Avkastning på investert kapital23.19%
Kontantavkastning på investert kapital21.19%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning18.40
Daglig høy18.40
Daglig lav18.12
Daglig volum229K
Tidenes høyeste41.63
1 år analytikerestimat22.24
Beta0.26
EPS (TTM)1.52
Utbytte per aksje-
Ex-div dato21 May 2024
Neste dato for resultatpresentasjon13 Feb 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
FAGR.BRS&P500
Nåværende prisfall fra toppnotering-56.48%-2.74%
Høyeste prisfall-90.66%-56.47%
Dato for høyeste fall14 Dec 20159 Mar 2009
Gj.snittlig fall fra topp-40.49%-11.13%
Gj.snittlig tid til ny topp39 days12 days
Maks tid til ny topp2659 days1805 days
SELSKAPSOPPLYSNINGER
FAGR.BR (Fagron NV) company logo
Markedsverdi
1.32B
Markedsverdi kategori
Small-cap
Beskrivelse
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Ansatte
3647
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Belgium
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regardin...
26. november 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...
10. oktober 2024
Fagron SA (ARSUF) reports robust revenue growth and improved margins, with significant gains in North America and an optimistic outlook for the full year.
9. oktober 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 200...
8. oktober 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program to...
13. september 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2...
6. september 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REB...
1. august 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutic...
13. mai 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board o...
12. april 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagr...
11. april 2024
Neste side